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Summary
Fine-needle aspiration cytology (FNAC) is an established, highly accurate, and cost-eff ective method for diagnosing 
lesions in the breast. The method is minimally invasive without unwanted side efect. FNAC forms part of the triple assess-
ment of breast lesions and has a high accuracy and sensitivity in dedicated centres. Method as a part of triple assessment has 
provide its value in describing the fi ndings most accurately. The diagnostic impact depends on experience of the operator, 
quality of preparation and diagnostic skills of the cytopathologist. Inadequate sampling with FNAC is particulary seen in 
collagenous lesions and in submitt ed specimens sampled by physicians lacking experience with the FNAC procedure. The 
highest accuracy is achived at centres with multidisciplinary approach.
The majority of European countries use similar reporting system for breast FNAC (C1-C5), in keeping with European 
guidelines for quality assurance in breast cancer screening and diagnosis. A clear reporting system ensures that an un-
equivocal cytological diagnosis of malignancy is reliable, and in cases where mammography/ultrasonography and clinical 
examination are in agreement with FNAC, frozen section examination is unnecessary.
The issue of optimal sampling to obtain adequate cell material in suffi  cient quantity is of paramount importance when 
assessing the accuracy of FNAC. The inadequate rates in FNAC from diff erent sources are lowest when FNAC is performed 
by a cytopathologist and highest when done by a non-cytopathologist. The multidisciplinary approach is necessary to am-
plify FNAC quality and to reduce its diagnostic limits. Only when this model of activity is not available, the role of FNAC 
is less eff ective and the addition of core biopsy (CB) to FNAC should be considered. CB as an alternative diagnostic modal-
ity should be used advisedly, in situations where it is more likely to yield diagnostic information, e.g., in the diagnosis of 
impalpable masses, microcalcifi cations or a clinically apparent malignancy where preoperative chemotherapy is planned. 
CB should not be used as a substitute for poor performance at FNAC. The methods are not mutually exclusive.
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ULOGA CITOLOGIJE U OTKRIVANJU I LIJEČENJU TUMORA DOJKE
Sažetak
Aspiracijska citologija tankom iglom (FNAC) je utemeljena, visoko pouzdana i jeftina metoda u dijagnostici lezija 
dojke. Metoda je minimalno invazivna bez neželjenih nuspojava. Sastavni je dio tz v. trojnog pristupa u dijagnostičkoj obra-
di lezija dojke, te u specijaliziranim centrima ima visoku pouzdanost i senzitivnost. Također je unutar trojnog pristupa do-
kazala svoju vrijednost mogućnošću da izrazito pouzdano okarakterizira promjene. Dijagnostički učinak ovisi o iskustvu 
liječnika koji izvodi postupak, kvaliteti obrade materijala te dijagnostičkim vještinama citopatologa. Neadekvatni uzorak se 
najčešće susreće u kolagenoznim lezijama,komplex sklerozirajućim promjenama te u oskudnosti primljenih materijalima od 
strane liječnika koji izvode punkciju, a nemaju dovoljno iskustva s procedurom. Najviša razina pouzdanosti postiže se u 
centrima s multidisciplinarnim pristupom. Većina europskih zemalja koristi isti sustav pisanja citoloških nalaza vezanih za 
dijagnostiku dojke (C1-C5), koristeći se smjernicama za osiguravanje kvalitete u probiru i dijagnostici karcinoma dojke. 
 Jasni sustav pisanja nalaza time osigurava pouzdanost nedvojbene citološke dijagnoze maligniteta, te u slučajevima kada je 
ona u skladu s radiološkim nalazima (mamografi jom/ultrazvukom), kao dio trojnog pristupa nije potrebna hitna, intropera-
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tivna patohistološka dijagnostika.Optimalno prikupljanje materijala radi dobivanja adekvatno celularnog uzorka, je od 
ključne važnosti za pouzdanost aspiracijske citologije( FNA). Nivo neadekvatnog materijala je najniži kada postupak izvodi 
citopatolog, a najveći kada ga izvode liječnici drugih specijalnosti. Multidisciplinarni pristup je neophodan za povećanje 
kvalitete metode te za reduciranje njenih dijagnostičkih ograničenja. Samo u slučajevima kada ovakav model pristupa nije 
dostupan, uloga citologije (FNA) je manje učinkovita te se treba uzeti u obzir biopsija širokom iglom (CB). CB je alternativni 
dijagnostički modalitet, te se treba koristiti ciljano, u situacijama kada je izvjesnije da će omogućiti bolju dijagnostičku infor-
maciju, npr. u slučajevima kada se radi o nepalpabilnim promjenama, mikrokalcifi katima, te u slučajevima klinički jasnog 
malignog procesa gdje se planira preoperativna kemoterapija. CB se ne treba koristiti kao alternativa slabo izvedenoj 
citološkoj punkciji, te se navedene dvije metode međusobno ne isključuju.
KLJUČNE RIJEČI: dojka, aspiracijska citologija, tumori dojke, dijagnoza
INTRODUCTION
Breast cancer is the lading cause of death 
among women. Incidence of breast cancer is rising 
in developed countries and the overall survival 
also shows a rising trend (1,2).
The introduction of breast screening pro-
grammes increased the use of minimally invasive 
diagnostic methods. True fi ne needles aspirations 
for breast diagnostics were fi rst introduced in the 
Karolinska Hospital in Stockholm. Franzen, who 
was an oncologist, introduced standard May-
Grunwald Giemsa stains on air –dried to allow 
rapid analysis . Despite their success, it was not 
until 1980s that fi ne needle aspiration cytology 
(FNAC) became widely used. Probably due to 
lack of confi dence in the sensitivity and specifi city 
of the procedure, fear of tumor implantation in the 
needle track, law-suits, and surgeons preferring 
histological biopsy for diagnosis (3). Now, FNAC 
is widely accepted technique and management of 
palpable and non-palpable breast lesions due to 
its simplicity, accuracy and utility for avoidance 
more invasive procedures.
The use of FNAC varies considerably in dif-
ferent centers. FNAC is commonly used as part 
of the triple diagnostic triad, along with clini-
cal breast examination and radiology immaging 
(mammography and ultrasonography). The diag-
nostic accuracy is close to 100% when all three mo-
dalities favor a benign or a malignant diagnosis 
(4). Therefore, fi ne needle aspiration (FNA) and 
core biopsy are now universally accepted as meth-
ods that virtually eliminate the need for open bi-
opsy or frozen sections in diagnosis of breast can-
cer. Nevertheless, growing number of analysis 
needed enlarged the faced cytologist/pathologist 
with certain challenges such as the reduced size of 
material obtained and wide variety of breast le-
sions that may be identifi ed.
Fine needle aspiration cytology
Fine-needle aspiration cytology in Croatia 
was the fi rst diagnostic method. According to the 
Croatian society for clinical cytology working 
Group guidelines, cytology report for breast tissue 
includes: adequacy of aspirated tissue, a descrip-
tion of the cells and tissue examined, cytological 
diagnosis, followed by patohistological confi rma-
tion of unclear, suspicious and malignant lesions. 
Cytology report should include information about 
tumor grade as a method of predicting histological 
grade and biological behaviour. The aim is to 
achieve the highest treatment accuracy (5).
Various cytological scoring systems exist. 
They are based on diff erent characteristics such 
as: cell cohesion, cellular pleomorphism, presence 
or lack of myoepithelial cells, mitotic count, nucle-
ar pleomorphism, presence of nucleoli and chro-
matin structure. Application of diff erent cytologi-
cal scoring methods as presented in table 1. and 
comparison with histological score as a golden 
standard, has proved that Robinson’s method of 
cytological scoring is easy to use and highly cor-
relates with histological score. Therefore it is a 
commonly used method for cytological scoring of 
breast cancer (6-9)
Robinson’s method encompasses six criteria 
presented in table 1. Each of the mentioned crite-
ria is assigned a number from 1 to 3. The sum of 
numbers att ached to each of the mentioned crite-
ria represents tumor grade; grade I: sum of 6-11, 
grade II: sum of 12-14, grade II: sum of 15-18. 
When comparing with other scoring systems, 
Robinson’s method includes more criteria and ex-
cludes necrosis and mitotic count which are diffi  -
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cult to detect in cytological specimen and hence 
provide unreliable information (9).
FNAC is performed with fi ne needle under 
ultrasound guidance. After the cells are with-
drawn by aspiration they are spread on a glass 
slide, they are air-dried and stained using May 
Grünwald-Giemsa method. The advantages of 
FNA are: quick, cheap and safe procedure with no 
need for local anaesteshia, minor complications 
and the results are rapidly available (10). Disad-
vantages are incomplete assessment of the tissue 
(when compared with histology) due to reduced 
cellularity in certain lesions (radial scar, lobular 
cancer and invasive breast cancer with sclerosis) 
(11). The diagnostic sensitivity, diagnostic speci-
fi city, overall accuracy, and the pseudo-negative 
and pseudo-positive results of FNAC for diag-
nosing breast carcinoma are 97.72%, 99.4%, 
97.94%, 2.28%, and 0.6%, respectively. The results 
depend upon the skills and education of the aspi-
rator. Inadequate rates (IR) in FNAC from diff er-
ent sources were compared by singh et al. The 
rates were lowest when FNAC was performed by 
a cytopathologist (12%) and highest when done 
by a non-cytopathologist (32%) (12).
Main problems are when there is equivocal/
borderline cytological diagnoses and that cases 
 always require a diagnostic biopsy. About good/
satisfactory breast FNAC we can talk when there 
is < 10 % unsatisfactory/nondiagnostic and when 
is a low percentage of equivocal/borderline diag-
noses (10-15 %).
Aspirator skill is refl ected mainly in the inad-
equacy rate which varies from < 5 % to 40%
Table 1.
ROBINSON’S METHOD OF CYTOLOGICAL GRADING
Count 1 Count 2 Count 3
Cohesion Cells mainly 
grouped
Mixed Cells mainly 
isolated
Cell size 1-2 x E 3-4 x E ≥ 5 x E
Cell uniformity monomorphism moderate pleomorfi sm
Nucleoli invisible barely 
visible
prominent
Nucleus margins smooth Frilled protruded, 
irregular
Cromatine vesicular granular lumpy
Gradus 3
Figure 1-3. Citology smears of invasive breast carcer graded 
 according to Robinson’s scale
Gradus I
Gradus 2.
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Some of the suspicious cases are also caused 
by suboptimal smear quality.
Reporting of Breast FNAC
The majority of European countries use the 
following reporting terminologies according to 
European guidelines for quality assurance in 
breast cancer screening and diagnosis C1-C5:
C1  –  insuffi  cient material/no diagnosis (unsatis-
factory)
C2  –  benign;
C3  –  equivocal (probably benign) (PBD without 
atypia), including
 – Columnar cell lesion/hyperplasia without 
atypia
 – Intraductal hyperplasia, adenosis, scleros-
ingadenosis, cellular papillary lesion
C4  –  suspicious NOS; PBD with atypia including
 – Consistent with non high-grade DCIS/ADH
 – Columnar cell hyperplasia with atypia
 – Consistent with papillary (intracystic) carci-
noma in situ,cannot evaluate invasiveness
C5  –  carcinoma NOS including
 – High-grade DCIS, cannot evaluate invasive-
ness
 – Invasive carcinoma (13,14)
This categorization helps cytopathologist to 
defi ne the uncertain areas, and the clinicians to of-
fer further investigation like excisional biopsy ju-
diciously. This categorization was initiated by the 
national coordinating committ ee for breast screen-
ing and the UK national breast screening program 
and serves as a common dialect among all breast 
health care professionals involved in breast man-
agement. (13)
A clear reporting system ensures that an un-
equivocal cytological diagnosis of malignancy is 
reliable, and in cases where mammography/ultra-
sonography and clinical examination are in agree-
ment with FNAC, frozen section examination is 
unnecessary. (13)
Adequate FNAC
The adequacy of FNAC is dependent on mul-
tiple factors. The rate of inadequate aspiration 
ranges from 0.7% to 25.3% and this is infl uenced 
by the nature of the lesion, the available technolo-
gy, and the experience and preference of the sur-
geon. It was reported that the nature of the lesion 
was the most common cause of inadequacy of 
FNAC, accounting for 68% of the inadequate aspi-
rates, followed by the experience of the aspirator 
that accounted for 32% of the inadequacy rate. 
During the procedure, patient’s cooperation is 
valuable, and a well-informed patient with good 
rapport with the operator for FNAC would great-
ly facilitate the procedure and improve the out-
come in terms of adequacy. Thus, each procedure 
should be patt erned and restricted to clinically 
and radiologically appropriate scenarios (14). 
Some studies advocated that both aspiratorand in-
terpreter should ideally be the same, as the num-
ber of inadequate aspirates was far lower and the 
accuracy of diagnosis was higher when the same 
person aspirated and reported on the specimens 
(14,15). The mean frequency of unsatisfactory as-
pirates by a nonpathologist was twice that when 
performed by a pathologist (15).
Unanimous defi nition of specimen adequacy 
in breast FNAC has not been reached so far. The 
National Cancer Institute (NCI) defi nition of ade-
quacy was one that led to resolution of a problem 
presented by a lesion in a particular patient’s 
breast. This defi nition was somewhat vague,being 
devoid of a quantifi able clause, but had the advan-
tage of being very fl exible and gave the aspirator 
the full mandate in deciding whether the cytologic 
features of the aspirate were consistent with the 
clinical fi ndings and deemed adequate (16). This 
would be particularly useful when both the aspi-
rator, and interpreter of the sample were the same. 
Most cytopathologists agree that a number of re-
lated parameters are signifi cant determinants of 
the adequacy of breast FNAC, and these include 
clinical and imaging fi ndings, size of the lesion, 
aspiration characteristics, experienceof the aspira-
tor, and the number of the needle passes (15).
Nevertheless, many authors considered epi-
thelial cell clusters as the most important adequa-
cy criteria. Studies demonstrated that an appro-
priate number of epithelial cell clusters could be 
an important factor in lowering the false-negative 
diagnosis rate in palpable and nonpalpable breast 
masses (15). It was further suggested that a cut-off  
of six epithelial cell clusters may provide a reason-
able balance between reduction of false-negative 
FNAC smears and an increase in the rate of inad-
equate smears (17).
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Sensitivity and specifi city
Fine needle aspiration cytology (FNAC) of 
the breast has two main goals. One is to confi rm a 
radiological and clinical benign lesion and avoid 
unnecessary surgery and the other is to confi rm a 
malignant diagnosis and allow defi nite treatment 
planning. FNAC of the breast is a standard diag-
nostic technique in diagnosis of breast benign and 
malignant changes as far as their further sub typ-
ing. FNAC diagnosis of the breast is reliable and 
accurate; it may be conveniently used in the clini-
cal practice since it provides indications for appro-
priate therapeutic procedures or diagnostic sur-
gery and avoid open biopsy. In the majority of 
studies evaluating FNA breast cytological accura-
cy, overall sensitivity was found to range from 
83% to 92% and specifi city between 92% and 98% 
according to Kocjan G (18). Therefore, FNAC is 
usually the fi rst morphological diagnostic test in 
institutions with high volume cytology. Ghimire 
reports that 98%, sensitivity 100%, specifi city 
95,2%, and positive predictive value of 96,7% can 
be achieved when FANC is a part of triple test 
(clinical examination and imaging) (5,19). These 
results were confi rmed in several institution 
where triple test, including cytology, is routinely 
performed (20,21). Furthermore, the technique is 
cost eff ective in stratifying breast lesions (20). 
FNAC is most widely used for confi rmation of 
 benign lesion, detection of recurrences, axillary 
lymph node analysis and intraoperative analysis 
of sentinel lymph node. However, it is vital to 
have an experienced team and high volume of 
breast pathology to achieve afore mentioned re-
sults as well as good quality checks and standard-
ized steps of analysis procedure
Indications for fi ne needle aspiration cytology
 – for patients with palpable lesions that concern 
the patient or her GP
 – especially for young patients with lesions per-
sistant after two menstrual cycles
 – for tumor masses in patients with history of 
breast cancer;
 – for radiologically detected, highly suspicious 
palpable lesions;
 – for atypical lumps reported cytologically or his-
tologically
 – for lesions suspicious for local recurrence 
(21,22)
FNAC and Core biopsy of the breast
During the last decade there has been a shift 
from FNAC to CNB, partly because of a generally 
lack of experienced cytopathologist and also be-
cause of some limitations and controversies about 
FNAC.
The use of needle core biopsy has gained a 
wide acceptance, particularly with the advent of 
stereotactic guidance. Use of smaller gauge nee-
dles has avoided the complications of trauma, 
pain, use of anaesthetic agents and tumor implan-
tation in a biopsy tract. With needle core samples, 
accurate subcategorization of carcinomas as well 
as study of hormone receptors and other prognos-
tic markers is possible (23). The false-positive rate 
with needle biopsy is very low (0.2–0.3%); it is 
slightly higher for nonpalpable lesions than for 
palpable ones (23). However, some lesions as fi -
broepithelial lesions, papillary lesions, ductal car-
cinoma in situ and atypical hyperplasia can cause 
diagnostic problems. The multidisciplinary ap-
proach is necessary to amplify FNAC quality and 
to reduce its diagnostic limits. Only when this 
model of activity is not available, the role of FNAC 
is less eff ective and the addition of core biopsy 
(CB) to FNAC should be considered. CB as an al-
ternative diagnostic modality should be used ad-
visedly, in situations where it is more likely to 
yield diagnostic information, e.g., in the diagnosis 
of impalpable masses, microcalcifi cations or a 
clinically apparent malignancy where preopera-
tive chemotherapy is planned. CB should not be 
used as a substitute for poor performance at 
FNAC. The methods are not mutually exclusive. 
Where there is access to skilled cytopathologists, 
FNAC and CB can complement each other and 
provide a highly accurate, rapid and cost-eff ective 
means of patient triage (24).
Both FNAB and core biopsy are valuable in 
the pre-operative diagnosis of impalpable breast 
lesions, and although FNAB is far less costly, ei-
ther technique is preferable to open biopsy in 
terms of morbidity and cost. Both of them are rec-
ognized as accurate diagnostic methods in sepa-
rating benign from malignant breast lesions with 
high sensitivity and specifi city. Where there is ac-
cess to experienced breast cytopathologists, the 
sequential use of the two techniques serves as 
a reliable and cost-eff ective means of triage for 
 selecting lesions that would benefi t most from 
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 assessment by core biopsy. Core biopsy supple-
ments FNAC and improves the rate of preopera-
tive diagnosis of highly suspicious mammo-
graphic microcalcifi cation (25,24).
Common limitations and interpretation errors 
by FNAC
The limitations of FNA can either be techni-
cal or related tothe nature of the lesion itself. Fur-
thermore, there are limitations that are specifi c to 
FNA regardless of technique or lesion type (i.e. 
intrinsic limitations).
Technical limitations
False-negative diagnoses can result in diag-
nostic delay and provide the patient with false re-
assurance. They may result from incorrect local-
ization, which can lead to nonrepresentative ma-
terial. This can be overcome by using imaging 
guidance. False-negative diagnoses may also re-
sult from improper technique, which can yield in-
adequate or suboptimal material. Contamination 
with blood can cause diffi  culties in interpretation. 
In addition, the preparation of a thin, uniform 
smear is equally important for accurate interpreta-
tion. It is very important that the person conduct-
ing the FNA is well trained in the technique. 
Sometimes, poor technique can mislead the un-
warypathologist into making a false-positive 
 diagnosis. Excessiveapplication of force while 
spreading the smear canlead to crushing and nu-
clear distortion and dissociation (i.e. crushing ar-
tefacts), which can result in the false impression of 
hyperchromasia. Also, delay in fi xation of the 
smear for Papanicolaou staining can result in cel-
lular enlargement; comparison with air-dried Gi-
emsa stained smears can be helpful in avoiding 
such false-positive diagnoses. Finally, poor quali-
ty staining can cause artefactual changes in the 
nature of the chromatin patt ern (23).
Limitations related to the lesion itself
Apart from technical problems, sometimes 
the nature of the lesion itself can cause diagnostic 
error. Some lesions share similar features on FNA 
and are diffi  cult to diff erentiate from each other. 
Cell atypia could be found in some benign breast 
lesions and cell specimens of in situ breast carci-
nomas, and well-diff erentiated carcinomas some-
times do not express cytomorphological features 
that would defi nitively indicate cell malignancy. 
A major obstacle is the lack of experienced cyto-
pathologist in many institution (26). Certain types 
of lesions can lead to false-negative diagnoses. For 
example, it is diffi  cult to fi x the small mobile le-
sion by hand, and thus it may be missed. Also, it is 
diffi  cult to aspirate fi brous lesions, and samples 
are oftenhypocellular and haemorrhagic. The 
smears may show only stromal fragments. Carci-
nomas can sometimes induce dense fi brotic stro-
ma, and in such cases a careful search for malig-
nant cells is necessary. The most common causes 
of false-positive FNAC diagnosis in breast pathol-
ogy are complex sclerosing lesions, wheresmears 
show small uniform cells with mild or no atypia. 
Complex sclerosing lesions and radial scars are 
regularly seen in mammography cases. Complex 
sclerosing lesions are usually moderately to high-
ly cellular with a pleomorphic patt ern.These are 
radiologicaly suspicious and may be mistaken for 
low-grade carcinomas.In the case of complex scle-
rosing lesions, presence of bare nuclei may be 
helpful in identifying the benign nature of the le-
sion.However, the presence of concurrent in situ 
or invasive carcinoma can be diffi  cult to diagnose. 
In a proportion of cases, further investigation with 
imaging modalities and core biopsies may be nec-
essary (27). In the case of necrotic and vascular le-
sions, the smears may notcontain any viable cells 
or may be haemorrhagic.Proliferative (adenosis, 
fi broadenoma, complex sclerosing lesion) and 
borderline breast lesions, such as columnar cell le-
sion and intraductal and intralobular epithelial 
proliferation, may present fi ndings that can be dif-
fi cult to distinguish from low-grade carcinomas. 
Fibroadenomas are well-known causes of false 
positive and false-negative diagnoses. Papillary 
lesions may harbor a spectrum of tumors, ranging 
from plain benign papilloma, via cellular papil-
lary lesions with and without cellular atypia, to 
papillary carcinomas (both in situ and invasive).
Fat necrosis, either post-traumatic or following 
surgery or radiotherapy or associated with mam-
mary duct ectasis or fi brocystic disease, is report-
ed to be another cause of both false- positive and 
false-negative FNAC diagnoses (28,29). Finally, 
smears from lobular carcinoma can be hypocellu-
lar and cells may not show signifi cant pleomor-
phism. Their resemblance to lymphocytes may 
result in false-negative diagnosis. Cytology of tu-
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bular carcinoma can resemble many benign con-
ditions, including adenoma, microglandular ade-
nosis and fi broadenoma (28). There are also types 
of lesions that can lead to false-positive diagnoses. 
In epithelial hyperplasia it is sometimes diffi  cult 
to diff erentiate between usual type hyperplasia, 
hyperplasia with atypia, and low-grade intraduct-
al carcinoma. Threedimensional clusters of cells 
with atypia can cause diagnostic problems. Also, 
with respect to fi broadenomas, hyperplastic foci 
can mimic low-grade carcinoma. Similarly, fi bro-
adenomas with myxoid degeneration can be mis-
taken for mucinous carcinoma(23). Cytologically, 
epithelial cells show mild nuclear pleomorphism 
with prominent nucleoliduring lactational chang-
es, which can be a cause of falsepositive diagnosis. 
Finally, iatrogenic changes following previous 
FNA/biopsy can result in false-positive diagnoses.
Stromal cells of granulation tissue, infl ammatory 
cells and histiocytes can mimic carcinomas. Simi-
larly, radiationinduced atypia in benign epitheli-
um can be worrisome.
Intrinsic limitations
There are a number of limitations that are in-
trinsic to FNA cytology. First, identifi cation of be-
nign fi broadenoma or frankly malignant phyl-
lodes tumour may not be diffi  cult, but distin-
guishing between cellular fi broadenoma and a 
phyllodes tumour can cause problems. Stromal 
cellularity and the presence of a number of long 
spindle cells may be helpful in some cases (30). 
Second, the cytological appearances of papillary 
lesions, which range from benign papilloma to in-
vasive papillary carcinoma, can be similar. In ad-
dition, benign papillomas can harbour areas of 
ductal carcinoma in situ. All papillary lesions need 
complete excision, and in our opinion the cytopa-
thologist should therefore not att empt to make a 
defi nitive diagnosis on the basis of FNA fi ndings, 
and often on the basis of a core biopsy as well, un-
less frank carcinoma is present. Third, it can some-
times be diffi  cult to distinguish between a muco-
cele- like lesion and mucinous carcinoma on cytol-
ogy. The presence of high cellularity, single or 
small three-dimensional groups of tumour cells, 
and cytological atypia should raise suspicion of 
carcinoma (31). Finally, in the absence of architec-
tural information, the distinction between ductal 
carcinoma in situ (DCIS) and invasive carcinoma 
may be diffi  cult cytologically.
Fat necrosis may be seen in most age groups 
and can persist for many years. Radiotherapy usu-
ally causes severe changes in both stromal cells 
and epithelial cells, which display hyperchromat-
ic cell nuclei that mimic malignant cells, but are 
usually few in number. Clinical history of per-
formed radiative therapy is important. Finally, 
lactational changes in benign lesions may be mis-
interpreted as malignant cells. Metastases to the 
breast are rare and the most frequent secondary 
tumor is malignant melanoma.
CONCLUSION
The use of minimally invasive and noninva-
sive methods in cytological diagnosis of breast 
cancer represents an integral component of the 
triple approach and is essential to the quality of 
the diagnostic process. An understanding of the 
limitations of the methods, and of their specifi city 
and sensitivity is very important in optimizing 
their use in a multidisciplinary environment.
The multidisciplinary approach is necessary 
to amplify FNAC quality and to reduce its diag-
nostic limits. Only when this model of activity is 
not available, the role of FNAC is less eff ective 
and the addition of core biopsy (CB) to FNAC 
should be considered. CB as an alternative diag-
nostic modality should be used advisedly, in situ-
ations where it is more likely to yield diagnostic 
information, e.g., in the diagnosis of impalpable 
masses, microcalcifi cations or a clinically appar-
ent malignancy where preoperative chemothera-
py is planned. CB should not be used as a substi-
tute for poor performance at FNAC. The methods 
are not mutually exclusive. Where there is access 
to skilled cytopathologists, FNAC and CB can 
complement each other and provide a highly ac-
curate, rapid and cost-eff ective means of patient 
triage.
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